TNYA

Business Context and Reporting Period

Tenaya Therapeutics, Inc. (TNYA) is a clinical-stage biotechnology company focused on developing curative therapies for heart disease. This Form 10-Q covers the quarterly period ended March 31, 2026. The company is classified as an emerging growth company and a smaller reporting company. Its lead product candidates include TN-201 (gene therapy for hypertrophic cardiomyopathy), TN-401 (gene therapy for arrhythmogenic right ventricular cardiomyopathy), and TN-301 (small molecule for heart failure and muscular dystrophy).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Recognition: The company recognized $0.2 million in collaboration revenue in Q1 2026, compared to none in Q1 2025. This was driven by a new collaboration agreement with Alnylam Pharmaceuticals entered into in March 2026, which included a $10.0 million upfront fee (recorded largely as a contract liability).
• Expense Reduction: Total operating expenses decreased by 26% ($7.2 million) year-over-year. Research and development (R&D) expenses dropped 30% to $14.8 million, and General and Administrative (G&A) expenses dropped 16% to $5.4 million. These reductions were primarily attributed to a workforce reduction implemented in March 2025.
• Liquidity Position: Cash and cash equivalents decreased by approximately $19.7 million during the quarter due to operating losses, though the company maintains a cash runway of at least 12 months.

Guidance, Outlook, and Risks

• Clinical Progress:
  • TN-201 (MyPEAK-1 Trial): Dosing in Cohorts 1 and 2 is complete. Interim data showed acceptable safety and evidence of sustained gene expression. Longer-term Cohort 1 and interim Cohort 2 data are expected in Q2 2026.
  • TN-401 (RIDGE-1 Trial): Dosing in Cohorts 1 and 2 is complete. Interim data indicated acceptable safety and reductions in premature ventricular contractions (PVCs) in some patients. One-year Cohort 1 data is expected in H1 2026.
  • TN-301: Preclinical data in Duchenne muscular dystrophy (DMD) models showed efficacy superior to the approved drug givinostat. The company plans to advance toward clinical trials.
• Collaboration: The Alnylam agreement involves a 24-month validation term for novel gene targets. Tenaya expects to recognize the remaining $10.0 million transaction price over this period.
• Capital Needs: Management expects to continue incurring net losses. While current cash is sufficient for 12 months, substantial additional funding will be required to complete development and commercialization.
• Listing Risk: The company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement ($1.00 per share). It has a 180-day grace period to regain compliance or risk delisting.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $80.9 million cash balance against the projected burn rate, considering the need for additional financing within the next 12 months.
• Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement within the 180-day grace period to avoid delisting.
• Alnylam Revenue Recognition: Track the amortization of the $10.0 million contract liability from the Alnylam deal to ensure it aligns with the 24-month validation timeline.
• Clinical Data Readouts: Confirm the timing and results of the upcoming Q2 2026 data presentations for TN-201 and H1 2026 data for TN-401, as these are critical for regulatory alignment.
• Workforce Reduction Impact: Assess whether the cost savings from the March 2025 workforce reduction are sustainable or if further reductions are anticipated.